MY163067A - Peg or peg block copolymers for treating colorectal cancer - Google Patents

Peg or peg block copolymers for treating colorectal cancer

Info

Publication number
MY163067A
MY163067A MYPI2013001602A MYPI2013001602A MY163067A MY 163067 A MY163067 A MY 163067A MY PI2013001602 A MYPI2013001602 A MY PI2013001602A MY PI2013001602 A MYPI2013001602 A MY PI2013001602A MY 163067 A MY163067 A MY 163067A
Authority
MY
Malaysia
Prior art keywords
peg
colorectal cancer
block copolymers
treating colorectal
treating
Prior art date
Application number
MYPI2013001602A
Other languages
English (en)
Inventor
Peter Stein
Ian Cox
Samuel Smith
Leighton Jones
Jörg Plessl
Vries Corinne De
Rachel Charlton
Original Assignee
Norgine Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norgine Bv filed Critical Norgine Bv
Publication of MY163067A publication Critical patent/MY163067A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/77Polymers containing oxygen of oxiranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
MYPI2013001602A 2010-11-04 2011-11-04 Peg or peg block copolymers for treating colorectal cancer MY163067A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1018650.0A GB201018650D0 (en) 2010-11-04 2010-11-04 Methods and compositions
US41212810P 2010-11-10 2010-11-10

Publications (1)

Publication Number Publication Date
MY163067A true MY163067A (en) 2017-08-15

Family

ID=43414365

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013001602A MY163067A (en) 2010-11-04 2011-11-04 Peg or peg block copolymers for treating colorectal cancer

Country Status (22)

Country Link
US (2) US20130216493A1 (enExample)
EP (1) EP2635289B1 (enExample)
JP (1) JP5917537B2 (enExample)
KR (1) KR20130109171A (enExample)
CN (1) CN103313719A (enExample)
AR (1) AR083770A1 (enExample)
AU (1) AU2011324996B2 (enExample)
BE (1) BE1019494A3 (enExample)
BR (1) BR112013011012A2 (enExample)
CA (1) CA2816839A1 (enExample)
EA (1) EA201300540A1 (enExample)
ES (1) ES2401269B1 (enExample)
GB (1) GB201018650D0 (enExample)
MX (1) MX349690B (enExample)
MY (1) MY163067A (enExample)
NL (1) NL2007715C2 (enExample)
NZ (1) NZ611145A (enExample)
SG (1) SG189533A1 (enExample)
TW (1) TWI606832B (enExample)
UA (1) UA107998C2 (enExample)
WO (1) WO2012059725A1 (enExample)
ZA (1) ZA201304052B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
NZ743984A (en) 2012-09-11 2019-10-25 Norgine Bv Compositions comprising polyethylene glycol, alkali metal or alkaline earth metal sulphates and electrolytes for use as colon cleansing compositions
AR093153A1 (es) * 2012-10-26 2015-05-20 Northshore Univ Healthsystem Composiciones que comprenden polietilenglicol para la terapia del carcinoma de celulas escamosas de cabeza y cuello
CN103083733A (zh) * 2013-02-19 2013-05-08 华熙福瑞达生物医药有限公司 一种医用体腔器械导入水性润滑剂
CN113507933B (zh) * 2019-03-05 2024-05-10 陶氏环球技术有限责任公司 诱导胱天蛋白酶活性
CN113473996B (zh) 2019-03-05 2024-05-24 陶氏环球技术有限责任公司 诱导胱天蛋白酶活性
JP7487220B2 (ja) * 2019-03-05 2024-05-20 ダウ グローバル テクノロジーズ エルエルシー カスパーゼ活性を誘導するためのポリエチレングリコール誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2784897B1 (fr) 1998-10-27 2002-11-29 Agronomique Inst Nat Rech Utilisation d'un laxatif osmotique non fermente dans le traitement et la prevention des cancers colorectaux
WO2006122104A1 (en) * 2005-05-06 2006-11-16 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
US8457025B2 (en) * 2009-08-28 2013-06-04 Telefonaktiebolaget L M Ericsson (Publ) Method and network node for selecting a network prefix to be advertised in a communication network

Also Published As

Publication number Publication date
AU2011324996B2 (en) 2015-10-08
EP2635289A1 (en) 2013-09-11
MX349690B (es) 2017-08-09
TW201304785A (zh) 2013-02-01
WO2012059725A8 (en) 2013-05-30
MX2013004963A (es) 2013-08-27
ES2401269A1 (es) 2013-04-18
AR083770A1 (es) 2013-03-20
CA2816839A1 (en) 2012-05-10
ES2401269B1 (es) 2014-02-19
CN103313719A (zh) 2013-09-18
ZA201304052B (en) 2014-02-26
UA107998C2 (uk) 2015-03-10
EA201300540A1 (ru) 2013-09-30
BE1019494A3 (fr) 2012-07-03
EP2635289B1 (en) 2020-03-11
TWI606832B (zh) 2017-12-01
WO2012059725A1 (en) 2012-05-10
JP2013544809A (ja) 2013-12-19
JP5917537B2 (ja) 2016-05-18
US20160228467A1 (en) 2016-08-11
BR112013011012A2 (pt) 2016-08-23
NL2007715A (en) 2012-05-07
SG189533A1 (en) 2013-05-31
KR20130109171A (ko) 2013-10-07
GB201018650D0 (en) 2010-12-22
AU2011324996A1 (en) 2013-05-02
NZ611145A (en) 2015-07-31
US20130216493A1 (en) 2013-08-22
NL2007715C2 (en) 2012-10-16

Similar Documents

Publication Publication Date Title
MY163067A (en) Peg or peg block copolymers for treating colorectal cancer
IL261338B (en) Preparations and methods for the treatment of wide-ranging, undifferentiated or mixed clinical applications
PH12013502195A1 (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
WO2012076293A9 (de) Zubereitungen enthaltend polysiloxane mit stickstoffhaltigen gruppen
PH12015501088A1 (en) Dimeric compounds
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
BR112012011485A2 (pt) "composições e métodos para tratar náusea e vômito centralmente mediados".
HK1210953A1 (en) Methods for treatment of atherosclerosis
WO2012078633A8 (en) Methods of inhibiting metastasis from cancer
WO2011088199A3 (en) Stabilization of zinc oxide film in oral compositions
WO2009095261A3 (en) Vaccine compositions
GB2496342B (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
WO2012073047A3 (en) Compositions and methods
PH12013501311A1 (en) Polymer systems
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists
WO2012074725A3 (en) Immunomodulatory methods and systems for treatment and/or prevention of hypertension
PH12015500399A1 (en) Azaindolines
EA201301205A1 (ru) Способ предупреждения и/или лечения плоскоклеточного рака головы и шеи и композиция в нем используемая
MX344189B (es) Formulaciones de mazindol.
MX356102B (es) Compuestos y métodos para tratar leucemia.
WO2012003030A3 (en) Methods of identifying & using anti-viral compounds
WO2010120400A3 (en) Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
TN2013000173A1 (en) Peg or peg block copolymers for treating colorectal cancer